JNJ
Johnson & JohnsonEvidence as of 2026-08-27The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on JNJ
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
7-day free trial. AI-written · every claim cites a source · Insight, not advice.
Overview · Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL aceta…
Management team
- Mr. Joseph J. Wolk CPA · Executive VP & CFOFind on LinkedIn
- Ms. Elizabeth Forminard J.D. · Executive VP & Chief Legal OfficerFind on LinkedIn
- Mr. James Swanson · Executive VP & Chief Information OfficerFind on LinkedIn
- Mr. Timothy Schmid · Executive VP & Worldwide Chairman of MedTechFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
−0.4 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.4 of a possible +2; was -0.4 before debate) with high confidence. Revenue increased from $ 24,062,000,000 in Q1 2026 (fiscal quarter ended 2026-04-17) to $ 25,310,000,000 in Q2 2026 (fiscal quarter ended 2026-07-17), and gross profit rose from $ 15,956,000,000 to $ 17,259,000,000 over the same two quarters, implying gross margin moved from about 66.4% to about 68.2%. Net income and diluted EPS both edged higher quarter-over-quarter — net income from $ 5,235,000,000 to $ 5,534,000,000 and diluted EPS from $ 2.14 to $ 2.27 — while shares outstanding ticked up by 2,681,626 shares and long-term noncurrent debt fell by $ 183,000,000.
Market- and valuation-related data in the packet show a mixed picture: momentum (12-1) is +62.4% and price is above both the 50- and 200-day moving averages, but EV relative to operating cash flow implies an EV/OCF of roughly 49.4x using the supplied enterprise value of $ 671,688,621,190 and trailing operating cash flow of $ 13,602,000,000; standard EV/EBITDA and price-to-FCF ratios cannot be computed from the supplied fields.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue reported for fiscal Q1 2026, ended 29 March 2026, was $24,062,000,000 and revenue for fiscal Q2 2026, ended 28 June 2026, was $25,310,000,000 (an increase of $1,248,000,000 quarter-over-quarter).
XBRL companyfacts · 0000200406-26-000087Gross profit for fiscal Q1 2026, ended 29 March 2026, was $15,956,000,000 and for fiscal Q2 2026, ended 28 June 2026, was $17,259,000,000 (an increase of $1,303,000,000); this implies gross margin rose from about 66.4% in fiscal Q1 2026 to about 68.2% in fiscal Q2 2026.
XBRL companyfacts · 0000200406-26-000153Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
The company added a risk stating its manufacturing requires timely delivery of complex, high-quality components and materials across 63 manufacturing facilities and thousands of suppliers, and that it has in the past, and may in the future, face unanticipated interruptions and delays in manufacturing from internal or external supply chain causes.
10-K filed 2026-02-11The company added a risk that the threat of counterfeit medicines could adversely impact business and reputation through reduced patient confidence, lost sales, product recalls, and increased litigation risk, and that diversion into unauthorized channels may reduce revenues and profitability.
10-K filed 2026-02-11Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum over the 12-1 signal is +62.4% and ranks in the 89th percentile of the 547-stock research universe on 2026-08-26.
Moneyta signal set · 2026-08-26weakened in debatePrice is above both moving averages: +5.1% vs the 50-day simple moving average and +16.5% vs the 200-day simple moving average, and the dataset flags a golden cross with the cross age at 286 days as of 2026-08-26.
Moneyta signal set · 2026-08-26weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Institutional 13F-reported holdings total $426.54B as of 2026-03-31 (13F filings carry a 45-day reporting lag).
13F holdings · 4594 filers · as of 2026-03-31Top institutional holders reported include BlackRock, Inc. with $52.16B, VANGUARD CAPITAL MANAGEMENT LLC with $38.28B, and STATE STREET CORP with $32.63B (as reported for the period ended 2026-03-31).
13F holdings · 4594 filers · as of 2026-03-31Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
On 2026-08-26 both finance.yahoo.com and zacks.com published the headline 'Top Analyst Reports for JPMorgan, Johnson & Johnson & Mastercard', indicating analyst-report coverage of Johnson & Johnson across at least two distinct outlets.
News · finance.yahoo.com · 2026-08-26A finance.yahoo.com article on 2026-08-26 reported that Johnson & Johnson closed a recent trading day at $270.27, a -1.05% move from the prior trading day, framing the coverage around a short-term stock dip relative to the broader market.
News · finance.yahoo.com · 2026-08-26Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Joaquin Duato (CEO and Chairman) reported sales totaling $26.7M for 102,315 shares and $5.5M for 20,976 shares on 13 August 2026 (two separate sales reported in the same filing), and additional sales of $10.8M for 41,957 shares and $1.7M for 6,523 shares reported on 5 August 2026; the filings show no trading plan flagged in the trading_plan field.
Form 4 · Duato Joaquin (CEO and Chairman of the Board) · $14.3M code M · 2026-08-13Joaquin Duato (CEO and Chairman) also reported a non-sale 'code M' transaction of $14.3M for 123,291 shares on 13 August 2026 in the same filing; the trading_plan field is null for that entry.
Form 4 · Duato Joaquin (CEO and Chairman of the Board) · $14.3M code M · 2026-08-13Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The trailing twelve-month price-to-earnings ratio is 30.61 (PE TTM = 30.61).
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve-month net cash provided by operating activities is $13,602,000,000 (NetCashProvidedByUsedInOperatingActivities = 13,602,000,000).
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Sequential operating results in the filings show quarter-over-quarter increases in revenue, gross profit, net income, and diluted EPS (fundamentals-0 through fundamentals-3), which, together with management disclosure that new products contributed meaningfully to 2025 sales and elevated R&D investment (filings-4), support a favorable reading of recent company fundamentals. Market signals — above both moving averages with a strong 12-1 momentum rank and a flagged golden cross (market-1, market-0) — align with the reported operating strength and are reinforced by substantial institutional ownership and broad analyst buy-side coverage (ownership-0, ownership-1, third-party street consensus). Cash and liquidity evidence (valuation-2) and a steady dividend yield with multi-year growth (market-5) provide additional context for the company’s financial flexibility. The strongest bearish points (insider sales, separation and supply-chain risks, and a high derived EV/OCF) have limitations in the supplied evidence: several insider entries are coded 'M' or lack trading-plan detail reducing interpretability, separation and supply-chain disclosures are acknowledged risk-language rather than evidence of realized impact, and the EV-to-operating-cash metric is a derived ratio computed without supplied FCF/EBITDA fields so its informational weight is limited.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.33
40 surviving claims rest on 18 distinct sources; the heaviest analyst carries 18% of them, and 96% of what the desk raised survived the debate.
The desk's read rests on a moderate breadth of sources (18 distinct citations) and most assertions survived internal debate, which increases confidence in the factual reporting. However, nearly all raised points surviving review means little internal contention but raises sensitivity to any shared-source or systemic errors; the largest single analyst influence is modest (under one-fifth), so no single analyst dominates the narrative.
Peer context · computed, not argued
12-1 momentum ranks 1st of 10 in Drug Manufacturers—General (as of 2026-08-26).
90-day volatility ranks 9th of 10 in Drug Manufacturers—General (as of 2026-08-26).
dividend yield ranks 6th of 10 in Drug Manufacturers—General (as of 2026-08-26).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
18 filings· 3 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.6 to the score
12 documents· 3 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−0.3 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.2 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.4 to the score
5 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
6 filings· 1 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot−1.2 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on JNJ Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.